Eric Sun | Biological Warfare - Lightning Talk @ Vision Weekend Puerto Rico 2026
Why It Matters
A low‑cost, easily administered nasal antibody could turn pandemic response from a reactive, vaccine‑dependent model into a proactive, population‑wide shield, reshaping bio‑security strategies worldwide.
Key Takeaways
- •Historical wars often lost due to disease, not combat
- •Current pandemic countermeasures rely on mRNA vaccines and IV antibodies
- •Public trust in mRNA tech has eroded, limiting vaccine uptake
- •Nasal spray immunoglobulins could cut dose cost to $0.20
- •Scalable nasal delivery could enable rapid, population‑wide bio‑defense
Summary
In a lightning talk at Vision Weekend Puerto Rico 2026, Eric Sun warned that pathogens have historically been the decisive factor in wars and argued that modern societies remain woefully unprepared for the next biological threat.
He cited Napoleon’s Haiti campaign, Pizarro’s conquest of the Incas, Attila’s failed invasion, and Cornwallis’s Yorktown defeat—all crippled by disease—to illustrate that microbes outpace conventional armies. Sun critiqued the post‑COVID response, noting that the U.S. invested heavily in mRNA vaccines and intravenously administered monoclonal antibodies, yet both approaches suffer from politicization, waning public trust, and logistical constraints.
Sun proposed nasal‑sprayed immunoglobulins as a game‑changing countermeasure. A milligram‑scale dose delivered to the upper airway could reduce manufacturing costs from $200 per treatment to roughly $0.20, enabling mass production for the entire U.S. or global population. He is currently designing antiviral molecules against the H3N2 strain and plans a Phase 1 trial next year, seeking grant partners and policy allies.
If realized, the technology would allow rapid, point‑of‑care prophylaxis or early‑stage therapy, dramatically shrinking the window for viral spread and strengthening civilizational resilience against biothreats. The proposal calls for coordinated public‑private investment and regulatory pathways to transform a niche biotech concept into a cornerstone of national security.
Comments
Want to join the conversation?
Loading comments...